linjc16/ctgov huggingface dataset:
The Effect of a Digital Photograph of the Patient in a CT Scan Examination on the Quality of Diagnosis by the Radiologist

Study Overview
=================
Brief Summary
-----------------
Whenever a scan is accessed through the PACS system a scanned document or digital picture may be displayed automatically. In this study the technician will take a digital picture of the patient who will be undergoing the CT scan. This way the radiologist will be able to view the patient's face before viewing the scan. The hypothesis is that viewing a digital picture of the patient before viewing the CT scan will improve the quality of diagnosis.

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who are to be scanned by ct Exclusion Criteria: Disabled
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
imaging
Implementation of Laparoscopy-assisted Surgery for Colon Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study the implementation of laparoscopy-assisted surgery for cure of colon cancer in daily surgical practice.

Detailed Description
-----------------
Prospective observational study of laparoscopy-assisted surgery for resectable colon cancer with regard to short term and long term outcomes

Official Title
-----------------
Implementation of Laparoscopy-assisted Surgery for Colon Cancer. A Prospective Population-based Study

Conditions
-----------------
Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >17 years diagnosis of colon cancer either endoscopically, radiologically or histologically proven No evidence of disseminated disease on CT scan T1-3 according to preoperative CT scan written informed consent to participate Exclusion Criteria: preoperative diagnosis of locally advanced tumor (T4) suspicion of pathological lymph nodes outside anticipated resection area contraindications against laparoscopic surgery, e.g. known bowel adhesions, anesthesiological concerns lack of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long term outcome | overall survival and cancer specific survival, time to relapse | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications related to the surgical procedure | Anastomotic leaks; intra-abdominal infections; extra-abdominal complications, i.e. non-surgical site infections, cardiovascular events, death within 30 days after surgery | 30 days | 
| Quality of life | Quality of life as assessed by SF-36 questionary | 1 year | 
| Quality of the surgical specimen | R0 resection or not; number of lymph nodes harvested | 14 days |
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664

Official Title
-----------------
Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors

Conditions
-----------------
Tumors

Intervention / Treatment
-----------------
* Drug: Brivanib
* Drug: Brivanib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologic/cytologic diagnosis of advanced or metastatic solid tumors ECOG 0-2 4/6 weeks since prior therapy Exclusion Criteria: Brain metastases Secondary primary malignancy Thromboembolic disease requiring full anticoagulation within 6 months Inability to swallow or absorb oral therapy Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME|
|Drug: Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absorption |  | Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10 | 
| Distribution |  | Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10 | 
| Metabolism |  | Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10 | 
| Elimination of BMS-582664 |  | Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess safety and tolerability of BMS-582664 800 mg administered daily in Part B |  | at last patient last visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced or metastatic solid tumors
Post-operative Cardiac Outcome of Non-cardiac Surgery Predicted by INVOS

Study Overview
=================
Brief Summary
-----------------
Research aimed to find a correlation with an invos drop and cardiac events in the peri-operative period of non cardiac surgery. The investigators postulate that a drop in the Invos numbers (with or without significant drop in BP) is associated with a variable degree of cardiac suffering. The idea is to prevent per and foremostpost-operative myocardial necrosis complications by acting as soon as we have an INVOS drop during anesthesia. The cardiac events will be monitored and defined according to the EHA (european heart association) guidelines. (Changes of the EKG and/or troponin I values above the threshold). Patient will be monitored per and post operatively.

Official Title
-----------------
Valeur Predictive de l'INVOS Sur l'Outcome Cardiaque en Post-opératoire. (French Title)

Conditions
-----------------
Invos, Peri-operative, Cardiac Outcome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female Age minimum 18 years old Exclusion Criteria: Chronic renal failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A composite measurement of major vascular events in the post-operative period | Myocardial infarction (measured by positivation of troponin I assay above the defined threshold) associated with clinical data (pain, dyspnea,...) or ST modification on the EKG or apparition of a new LBBB, or new wall abnormalities on the TTE. Or new TIAs or CVAs | 96 hours post-operative |
Sequential Compression Device on Body Temperature

Study Overview
=================
Brief Summary
-----------------
We hypothesized that sequential compression device (SCD) compression system might induce more decreases on core temperature by increasing lower extremity blood flow. And, this study investigated the effects of SCD compression system on body temperature in patients during total intravenous anesthesia (TIVA) with propofol and remifentanil.

Detailed Description
-----------------
Anaesthesia was induced and maintained with propofol and remifentanil. During the surgery, temperature was measured and recorded using oesophageal temperature and the calf-minus-toe skin-surface temperature gradient, respectively.

Official Title
-----------------
The Effects of Sequential Compression Device on Body Temperature During Propofol Anaesthesia: A Comparison With Elastic Stockings

Conditions
-----------------
Hypothermia

Intervention / Treatment
-----------------
* Device: sequential compression device
* Device: elastic stockings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I or II 20-65 year patient who undergoing elective thyroidectomy Exclusion Criteria: coronary occlusive disease peripheral vascular disease BMI > 30 kg/m2 abnormal thyroid function test laparoscopic assisted thyroidectomy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: sequential compression device<br>Apply sequential compression device during the thyroidectomy | Device: elastic stockings<br>* applying elastic stockings during the surgery<br>* Other names: ES;|
| Experimental: elastic stockings<br>Apply elastic stockings during the thyroidectomy | Device: sequential compression device<br>* applying sequential compression device during the surgery<br>* Other names: SCD;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Core Body Temperature | Core temperature and arteriovenous shunt in the lower leg was measured using oesophageal temperature and the calf-minus-toe skin-surface temperature gradient. | from baseline record core temperature every 15 minutes up to operative end | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
core temperature, sequential compression device, total intravenous anesthesia
Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether atorvastatin, aggressive lifestyle intervention, and their interaction are effective in delaying the progress of pre-clinical atherosclerosis.

Detailed Description
-----------------
Primary prevention of atherosclerotic disease remains a big challenge. Currently, it is not clear how to treat those subjects with evidence of pre-clinical atherosclerosis but without obvious conventional risk factors. This randomized, placebo controlled, double blind study is to evaluate the effect of Atorvastatin 10 mg daily, therapeutic lifestyle change, and their combination, on the progression of CIMT in those with higher baseline CIMT value but are not belong to 'high risk' category, according to the conventional risk factors.

Official Title
-----------------
Effect of Atorvastatin and Lifestyle Intervention on Progression of Carotid Intima-Media Thickness in Chinese People Without Manifest Atherosclerotic Disease

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Drug: Atorvastatin
* Behavioral: Aggressive lifestyle intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CIMT is not less than 0.9 mm without Clinical diagnosis of atherosclerotic disease without Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: P+N<br>placebo without lifestyle intervention | |
| Experimental: D+N<br>Atorvastatin 10mg/d | Drug: Atorvastatin<br>* atorvastatin 10mg/d<br>|
| Experimental: P+A<br>lifestyle intervention without Atorvastatin | Behavioral: Aggressive lifestyle intervention<br>* aggressive lifestyle intervention<br>|
| Experimental: D+A<br>lifestyle intervention and Atorvastatin 10mg/d | Drug: Atorvastatin<br>* atorvastatin 10mg/d<br>Behavioral: Aggressive lifestyle intervention<br>* aggressive lifestyle intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The progress of CIMT |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The progress of ABI |  | 2 years | 
| The progress of PWV |  | 2 years | 
| Occurrence of atherosclerotic disease |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atherosclerosis, Atorvastatin, Therapeutic lifestyle change, CIMT, ABI, PWV
Effects of Intensive Upper and Lower Limbs Motor Control Therapy in Cerebral Palsy Children

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine the effetiveness of the intensive upper and lower limbs therapy to improve the funtional outcomes and to minimize ther energetic spendings during funtional activities in Cerebral Palsy patients.

Detailed Description
-----------------
The aim of the study is to determine the effetiveness of the intensive upper and lower limbs therapy to improve the funtional outcomes and to minimize ther energetic spendings during funtional activities in Cerebral Palsy patients. Also to know paretns and caregivers perceptions.

Official Title
-----------------
Effects of Intensive Upper and Lower Limbs Motor Control Therapy in Cerebral Palsy Children

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Other: Intensive bimanual therapy
* Other: Intensive neurodevelopmental therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral Palsy Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intensive bimanual therapy<br>Ninety hours of intensive bimanual therapy | Other: Intensive bimanual therapy<br>* Ninety hours of intensive bimanual therapy<br>|
| Active Comparator: Neurodevelopmental treatment<br>Ninety hours of intensive neurodevelopmental therapy | Other: Intensive neurodevelopmental therapy<br>* Ninety hours of intensive neurodevelopmental therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arm Funtion | Assissting Hand Assessment Instrument (AHA) | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Funtional Activity | Jebsen Taylor Hand Funtion Test | 6 months | 
| Perception of performance in everyday living | Canadian Occupational Performance Measure (COMP) | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intensive Therapy, Cerebral Palsy
Optimization of Bedside Chest X-rays Taken in the Intensive Care Unit by Using Current Software-based Techniques

Study Overview
=================
Brief Summary
-----------------
This study investigates how to utilize an algorithm-based virtual grid in lung imaging in intensive care unit patients. The aim is to compare the radiation dose caused by imaging with a virtual grid and a traditional grid and relate this to the achieved image quality. The study aims to determine how the radiation dose can be lowered and still obtain the same diagnostic image quality as using a traditional scatter-limiting lattice.

Official Title
-----------------
Optimization of Bedside Chest X-rays Taken in the Intensive Care Unit by Using Current Software-based Techniques

Conditions
-----------------
X-Rays

Intervention / Treatment
-----------------
* Radiation: X-ray image


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients in the intensive care unit with an imaging of the lung. Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Taditional Grid<br>Patients imaged with traditional grid | Radiation: X-ray image<br>* Bedside x-ray at intensive unit.<br>|
| Virtual Grid<br>Patients imaged with virtual grid | Radiation: X-ray image<br>* Bedside x-ray at intensive unit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image quality | Compare the radiation dose caused by imaging with a virtual grid and a traditional grid and relate this to the achieved image qualit | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Imaging, Grid, X-ray, Image quality
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the Fetal Medicine Foundation algorithm for individual risk calculation for preeclampsia (PE) and pregnancy induced hypertension (PIH) is suitable to identify women in high risk of developing these diseases in a Norwegian population.

Detailed Description
-----------------
It has been shown that low dose acetylsalicylic acid (ASA) in pregnancy reduces adverse outcome of pregnancy in women that have high risk of developing preeclampsia (PE). It is a challenge for the clinician to identify the high risk women. Doppler blood flow measurements in uterine arteries in second trimester have been shown useful to predict the development of the disease but prophylactic treatment with ASA from this point in pregnancy has not been proven effective. Fetal Medical Foundation has developed an algorithm that calculates individual risks for PE/ PIH based on Doppler blood flow measurements and anamnestic information.

Official Title
-----------------
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant Nulliparous Para 1+ with previous preeclampsia or gestational hypertension last menstrual period (LMP) pregnancy length at inclusion < 13 weeks Residence in Trondheim + 8 surrounding municipalities Exclusion Criteria: Pregnancy length > 13+6 weeks (CRL > 85 mm) Twins Missed abortion Fetal anomaly

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of preeclampsia |  | september 2012 | 
| Onset time of preeclampsia |  | September 2012 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestational age at delivery |  | September 2012 | 
| Number of induction of deliveries due to preeclampsia |  | September 2010 | 
| Number of instrumental deliveries due to preeclampsia |  | September 2012 | 
| Perinatal morbidity |  | September 2012 | 
| Maternal morbidity |  | September 2012 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preeclampsia, Doppler ultrasound, First trimester, Acetylsalicylic acid
A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia

Study Overview
=================
Brief Summary
-----------------
This study will hypothesize that the use of a self fixating lightweight mesh in open inguinal repair is feasible in the Philippine setting. It will result in a comparable recurrence rate as published for the traditional Lichtenstein approach.

Detailed Description
-----------------
The specific aim of this study is to assess the feasibility of using a self fixating lightweight mesh in open inguinal hernia under both under regional and local anesthesia in the Philippines. The primary endpoint of which is to assess the recurrence rate at 2 years (with an interim analysis 1 year after the procedure). Secondary endpoints would be to gather data with regards to postoperative pain, post operative surgical complications, wound healing complications, operating factors (mesh deployment time, total operating time), hernia factors (type and size of inguinal hernia).

Official Title
-----------------
A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia

Conditions
-----------------
Hernia, Inguinal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 years Informed consent Primary inguinal hernia suitable for open inguinal repair Reducible hernia Exclusion Criteria: Incarcerated non reducible hernias Bleeding disorders Patients below 18 (lower age limit) and above 80 (upper age limit) years old Hernia defects of greater than 4 cm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inguinal Hernia, Self-fixating mesh, Progrip, Hernia Recurrence, Mesh, Surgical, Recurrence